The Sirtuin 3 Expression Profile Is Associated with Pathological and Clinical Outcomes in Colon Cancer Patients

Abstract EN

Aim.

To investigate the correlation between Sirtuin 3 (SIRT3) expression and the clinical outcome of patients with colon cancer.

Methods.

The tumor specimens from 127 patients with colon cancer were obtained for SIRT3 immunohistochemical staining.

Patients were followed up.

In in vitro study, SIRT3 gene was inhibited to observe the effects of SIRT3 on the biological behavior of cultured colon cells.

Results.

The SIRT3 expression level was found to be significantly associated with the lymph node metastasis (P<0.001) and tumor stages (P<0.001).

The colon cancer-specific survival was 64.6% among patients with high SIRT3 expressions and 88.6% among patients with low SIRT3 expressions (log-rank P=0.016).

The overall survival was 80.2% among patients with low SIRT3 expressions and 55.9% among patients with high SIRT3 expressions (log-rank P=0.002).

In vitro study showed that silencing of SIRT3 gene inhibited the proliferation, invasion, and cells migration but increased the apoptosis in the cultured colon cell lines.

Conclusion.

This study provides evidence supporting that SIRT3 is closely associated with the clinical outcomes of colon cancer.

SIRT3 may be considered as a marker for colon cancer.